HomeComparePIFFY vs PFE

PIFFY vs PFE: Dividend Comparison 2026

PIFFY yields 3.66% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PIFFY wins by $168.7K in total portfolio value
10 years
PIFFY
PIFFY
● Live price
3.66%
Share price
$8.37
Annual div
$0.31
5Y div CAGR
46%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$218.3K
Annual income
$98,266.63
Full PIFFY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PIFFY vs PFE

📍 PIFFY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPIFFYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PIFFY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PIFFY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PIFFY
Annual income on $10K today (after 15% tax)
$311.08/yr
After 10yr DRIP, annual income (after tax)
$83,526.64/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PIFFY beats the other by $61,206.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PIFFY + PFE for your $10,000?

PIFFY: 50%PFE: 50%
100% PFE50/50100% PIFFY
Portfolio after 10yr
$133.9K
Annual income
$62,262.68/yr
Blended yield
46.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PIFFY
No analyst data
Altman Z
2.5
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PIFFY buys
0
PFE buys
0
No recent congressional trades found for PIFFY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPIFFYPFE
Forward yield3.66%6.13%
Annual dividend / share$0.31$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR46%13.2%
Portfolio after 10y$218.3K$49.6K
Annual income after 10y$98,266.63$26,258.71
Total dividends collected$184.5K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PIFFY vs PFE ($10,000, DRIP)

YearPIFFY PortfolioPIFFY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,234$534.32$9,153$693.39+$2.1KPIFFY
2$12,840$819.07$8,593$849.25+$4.2KPIFFY
3$15,016$1,277.32$8,336$1,066.78+$6.7KPIFFY
4$18,105$2,038.27$8,437$1,384.80+$9.7KPIFFY
5$22,726$3,353.39$9,013$1,875.40+$13.7KPIFFY
6$30,060$5,743.44$10,306$2,680.72+$19.8KPIFFY
7$42,530$10,365.98$12,820$4,101.38+$29.7KPIFFY
8$65,519$20,011.82$17,673$6,826.70+$47.8KPIFFY
9$112,171$42,065.46$27,543$12,591.86+$84.6KPIFFY
10$218,290$98,266.63$49,560$26,258.71+$168.7KPIFFY

PIFFY vs PFE: Complete Analysis 2026

PIFFYStock

PT Indofood CBP Sukses Makmur Tbk, together with its subsidiaries, produces and sells consumers products in Indonesia, rest of Asia, the Middle East, Africa, and internationally. It offers noodles, sauces, and instant seasonings under the Indomie, Supermi, Sarimi, Pop Mie, Sakura, and Mi Telur Cap 3 Ayam brands, as well as sweetened condensed milk; UHT, sterilized bottled, and pasteurized liquid milk; powdered milk; ice cream; and butter under the Indomilk, Cap Enaak, Tiga Sapi, Kremer, Orchid Butter, Indofoof Icecream, Good To Go, and Milkuat brands. The company also provides chips and non-chips snacks, such as potato-based biscuits, cassavas, and wheat flour under the Chitato, Qtela, Chiki, Jetz, Trenz, Chitato Lite, and Maxicorn brands; and food seasonings, including powdered and liquid seasonings, condiments, and syrups under the Sambal Indofood, Bumbu Special Indofood, Bumbu Racik, Indofood Freiss, and Kecap Indofood brands. In addition, it offers nutrition and special foods, such as baby cereals, follow-on cereals, noodle soups, and baby biscuits, as well as fortified milk for expectant and lactating mothers under the Promina, Sun, Govit, and Gowell brands; and beverages comprising tea, packaged water, and fruit-flavored drinks under the brands of Ichi Ocha, Club, and Fruitamin. Further, the company manufactures packaging materials and non-alcoholic beverages; markets and distributes culinary products; processes oil and fats; manages restaurants; and provides investment and trade export agency, management consulting, general trading, and transportation services. Additionally, it produces and distributes of dairy products and industrial estate. The company was founded in 1982 and is headquartered in Jakarta, Indonesia. PT Indofood CBP Sukses Makmur Tbk is a subsidiary of PT Indofood Sukses Makmur Tbk.

Full PIFFY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PIFFY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PIFFY vs SCHDPIFFY vs JEPIPIFFY vs OPIFFY vs KOPIFFY vs MAINPIFFY vs JNJPIFFY vs MRKPIFFY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.